|
Apr 23
|
Trending tickers: Tesla, ABF, Novartis, Taylor Wimpey, JD Sports
|
|
Apr 23
|
UPDATE 1-Healthcare, tech stocks boost STOXX 600 to one-week high
|
|
Apr 23
|
Novartis Raises Guidance on Profit, Sales Growth
|
|
Apr 23
|
Techs boost STOXX to one-week high; euro zone data on tap
|
|
Apr 23
|
UPDATE 4-Novartis raises guidance after beating Q1 expectations
|
|
Apr 23
|
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
|
|
Apr 22
|
Top Analyst Reports for Novartis, American Express & ConocoPhillips
|
|
Apr 19
|
Novartis (NVS) to Report Q1 Earnings: What to Expect?
|
|
Apr 18
|
US FDA mandates label updates on CAR-T cancer therapies
|
|
Apr 18
|
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
|
|
Apr 17
|
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
|
|
Apr 17
|
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
|
|
Apr 16
|
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
|
|
Apr 15
|
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
|
|
Apr 14
|
Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.
|
|
Apr 12
|
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
|
|
Apr 11
|
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
|
|
Apr 11
|
Novartis (NVS) to Undertake Job Cuts in Development Department
|
|
Apr 11
|
UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion
|
|
Apr 11
|
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
|